<DOC>
	<DOC>NCT02656173</DOC>
	<brief_summary>The primary objective of the study is to investigate the efficacy of mirabegron versus placebo in male patients with OAB symptoms while taking the alpha blocker, tamsulosin, for BPH.</brief_summary>
	<brief_title>A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<mesh_term>Adrenergic alpha-Antagonists</mesh_term>
	<criteria>at Visit 1 (Screening): Patient has been under treatment with tamsulosin 0.2mg for at least 4 weeks before the start of the Screening period Patient with a history of an average of at least 2 episodes of urgency per 24 hours and an average of 8 or more micturitions per 24 hours during the last 3 days before the start of the Screening period (verified by interview). Patient who has no wish to have children in the future (Unique to Japan). Male subjects and their female spouses/partners who are of childbearing potential must be using highly effective contraception consisting of two forms of birth control (at least one of which must be a barrier method), starting at Screening, continuing throughout the study period, and for 28 days after the final study drug administration. Subject must not donate sperm, starting at Screening, continuing throughout the study period, and for 28 days after the final study drug administration. Patient is willing and able to complete the micturition diary and questionnaires correctly. Subject agrees not to participate in another interventional study while receiving treatment in this study. at Visit 2 (Baseline): Subject with an average of at least 2 episodes of urgency per 24 hours and an average of 8 or more micturitions per 24 hours based on a 3day micturition diary from the Screening period. at Visit 1 (Screening): Patient with suspected symptoms of OAB, with onset only transient (e.g., druginduced, psychogenic). Patient with PVR urine volume &gt;100 mL or Q max &lt;5 mL/sec. Patient with prostatespecific antigen (PSA) ≥4 ng/mL. Patient with neurogenic bladder (e.g., spinalcord lesions or other damage that will clearly affect urination; multiple sclerosis; Parkinson's disease) or a history of surgery that caused damage to the pelvic plexus. Patient with urethral stricture or bladderneck stenosis. Patient with diabetic neuropathy complications. Patient who has undergone a surgical procedure, previous pelvic radiation therapy, or hyperthermia therapy that may affect urinary tract function. Patient with significant stress incontinence or postsurgical prostate incontinence, as determined by the Investigator. Patient with an indwelling catheter or practices intermittent selfcatheterization. Patient with 3 or more episodes of recurrent urinary tract infection (UTI) within the last 6 months. Patient with a UTI; prostatitis; chronic inflammation, such as interstitial cystitis; urinary calculus; or previous or current malignant disease of the pelvic organs. Patient with a concurrent malignancy or history of any malignancy (within the past 5 years), except for nonmetastatic basalcell or squamouscell carcinoma of the skin that has been treated successfully. Patient with serious heart disease, liver disease, kidney disease, immunological disease, lung disease. Patient who has received intravesical injection within the last 12 months with botulinum toxin, resiniferatoxin, or capsaicin. Patient who has received electrostimulation therapy for OAB. Patient who has received a bladder training program or pelvic floor exercises &lt;28 days prior to the start of the Screening period. Patient with postural hypotension or syncope, hypokalemia, or closedangle glaucoma. Patient with evidence of QT prolongation on electrocardiogram (ECG), defined as QTcF &gt;450 msec. Patient with severe uncontrolled hypertension, defined as sitting systolic blood pressure (SBP) &gt;180 mmHg and/or diastolic blood pressure (DBP) &gt;110 mmHg. Patient with a clinically significant ECG abnormality, as determined by the Investigator. Patient who has severe renal impairment, defined as an estimated glomerular filtration rate of &lt;29 mL/min/1.73m2; endstage renal disease; or is undergoing dialysis. Patient with aspartate transaminase (AST) or alanine transaminase (ALT) &gt;2 times the upper limit of normal (ULN), or gammaglutamyl transferase (γGT) &gt;3 times the ULN and considered clinically significant by the Investigator. Patient with moderate or severe hepatic impairment, defined as ChildPugh Class B or C. Patient with hypersensitivity to any of the components of mirabegron, other betaadrenergic receptor (βAR) agonists, or any of the inactive ingredients. Patient with ongoing alcohol and/or drug abuse. Patient with or a history of mood disorder, neurotic disorder, or schizophrenia. Patient with dementia, cognitive dysfunction, or clinically significant cerebrovascular disorder. Patient who has been treated with an experimental device &lt;84 days or received an investigational agent &lt;84 days prior to the start of the Screening period. Patient has used any prohibited concomitant medication &lt;28 days (but, &lt;1 year for 5αreductase inhibitors) before the start of the Screening period. Patient with any clinically significant condition, which in the opinion of the Investigator, makes the subject unsuitable for study participation. Patient who is involved in the conduct of the study as an employee of the Astellas group, a third party associated with the study, or the study site team. at Visit 2 (Baseline): Subject fulfills any exclusion criteria of Visit 1 at Visit 2. Subject was noncompliant during the 4 week tamsulosin Screening period, defined as taking less than 80% or greater than 120% of prescribed dose of study medication. Subject had an average total daily urine volume &gt;3000 mL, as recorded in the 3day micturition diary.</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Tamsulosin</keyword>
	<keyword>Overactive bladder</keyword>
	<keyword>Benign prostatic hypertrophy</keyword>
	<keyword>Mirabegron</keyword>
</DOC>